Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on ASND stock, giving a Buy rating yesterday.
Joseph Schwartz has given his Buy rating due to a combination of factors that highlight the potential of Ascendis Pharma’s Yorvipath in the hypoparathyroidism market. The recent CALYPSO trial results for AstraZeneca’s eneboparatide, while meeting primary endpoints, have not fully clarified the risk-benefit profile, which is seen as a positive for Yorvipath. Ascendis Pharma’s Yorvipath has shown a strong launch with a significant number of prescriptions in the U.S., indicating a promising market presence.
Despite some concerns about the competitive landscape, the limited data disclosure from AstraZeneca suggests that Yorvipath may have an advantage. Questions remain about eneboparatide’s mechanism and potential long-term benefits, which could favor Yorvipath’s ongoing success. These factors contribute to the confidence in Ascendis Pharma’s stock, supporting the Buy rating.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $162.00 price target.